Regeneron Pharmaceuticals presented early clinical data on Lynozyfic, a T cell engager demonstrating a 100% response rate in patients with smoldering multiple myeloma. The results mark a promising advancement in treating this precancerous stage that can progress to active multiple myeloma. Lynozyfic’s efficacy supports Regeneron’s strategy to expand T cell engager applications in hematologic malignancies. Further trials are underway to evaluate durability and safety.